The Patent Finder
NO

Novavax, Inc.

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

32 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in May 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
May 2028
Next term end
11
Patent families

When these terms end

Held patents by the year their term ends
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 1, 2027
    The maintenance fee for Vaccine Compositions Having Improved Stability and Immunogenicity (US 10,426,829) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
  • 1 fee due May 26, 2027
    The maintenance fee for Influenza Vaccine (US 10,485,863) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 2 fees due Aug 13, 2027
  • 1 fee due Sep 26, 2027
    The maintenance fee for Methods and Compositions for Inducing Immune Responses Against Clostridium Difficile (US 11,938,179) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 18, 2026
  • 3 terms have ended since Aug 18, 2026

What they patent

The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,381,239Novel VLPS Derived from Cells That Do Not Express a Viral Matrix or Core Protein
In force
 · High confidence
In forceHigh confidence
US 8,697,088Novel VLPS Derived from Cells That Do Not Express a Viral Matrix or Core Protein
In force
 · High confidence
In forceHigh confidence
US 9,675,685Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 9,717,786Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 9,731,000Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 10,022,437Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 11,052,146Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 11,446,374Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 12,357,684Modified RSV F Proteins and Methods of Their Use
In force
 · High confidence
In forceHigh confidence
US 10,736,958Influenza Vaccine
held by Novavax AB
In force
 · High confidence
In forceHigh confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 1 patent in force now held by others · 31 patents ended · 28 applications pending · 38 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited